Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficiency of Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer (PROC): An Umbrella Study

NCT05044871 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT05044871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05044871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficiency of Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer (PROC): An Umbrella Study
Lead sponsor
Tongji Hospital
Phase
Phase 2
Overall status
Completed
Start date
July 22, 2022
Completion date
February 17, 2025
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer